Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-05-022204
Filing Date
2005-05-10
Accepted
2005-05-10 16:17:36
Documents
10
Period of Report
2005-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q a05-8150_110q.htm 10-Q 620181
2 EX-10.16 a05-8150_1ex10d16.htm EX-10.16 14200
3 EX-10.19 a05-8150_1ex10d19.htm EX-10.19 10451
4 EX-10.22 a05-8150_1ex10d22.htm EX-10.22 10450
5 EX-10.28 a05-8150_1ex10d28.htm EX-10.28 54547
6 EX-10.32 a05-8150_1ex10d32.htm EX-10.32 10713
7 EX-31.1 a05-8150_1ex31d1.htm EX-31.1 13585
8 EX-31.2 a05-8150_1ex31d2.htm EX-31.2 14174
9 EX-32.1 a05-8150_1ex32d1.htm EX-32.1 5763
10 EX-32.2 a05-8150_1ex32d2.htm EX-32.2 5766
  Complete submission text file 0001104659-05-022204.txt   761275
Mailing Address 300 ELLIOTT AVENUE WEST SUITE 500 SEATTLE WA 98119-4114
Business Address 300 ELLIOTT AVENUE WEST SUITE 500 SEATTLE WA 98119-4114 2062817001
NEORX CORP (Filer) CIK: 0000755806 (see all company filings)

EIN.: 911261311 | State of Incorp.: WA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-16614 | Film No.: 05816912
SIC: 2835 In Vitro & In Vivo Diagnostic Substances